Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adults
View ORCID ProfileYara Yakoub, View ORCID ProfileFernando Gonzalez-Ortiz, View ORCID ProfileNicholas J. Ashton, Christine Déry, View ORCID ProfileCherie Strikwerda-Brown, Frédéric St-Onge, View ORCID ProfileValentin Ourry, View ORCID ProfileMichael Schöll, Maiya R. Geddes, Simon Ducharme, Maxime Montembeault, View ORCID ProfilePedro Rosa-Neto, View ORCID ProfileJean-Paul Soucy, View ORCID ProfileJohn C.S. Breitner, View ORCID ProfileHenrik Zetterberg, View ORCID ProfileKaj Blennow, View ORCID ProfileJudes Poirier, View ORCID ProfileSylvia Villeneuve, PREVENT-AD Research Group
doi: https://doi.org/10.1101/2024.05.09.24307120
Yara Yakoub
1Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer’s Disease (StoP-AD), Montreal, Quebec, Canada
BScFernando Gonzalez-Ortiz
2Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
MDNicholas J. Ashton
2Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
3Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
4King’s College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK
5NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK
PhDChristine Déry
1Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer’s Disease (StoP-AD), Montreal, Quebec, Canada
MScCherie Strikwerda-Brown
1Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer’s Disease (StoP-AD), Montreal, Quebec, Canada
6School of Psychological Sciences, The University of Western Australia, Perth, Australia
PhDFrédéric St-Onge
1Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer’s Disease (StoP-AD), Montreal, Quebec, Canada
PhDValentin Ourry
1Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer’s Disease (StoP-AD), Montreal, Quebec, Canada
PhDMichael Schöll
2Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
3Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
7Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
PhDMaiya R. Geddes
8Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
9Massachusetts Institute of Technology, Cambridge, MA, USA
10McGill Center for Research Studies in Aging, Montreal, Quebec, Canada
MDSimon Ducharme
1Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer’s Disease (StoP-AD), Montreal, Quebec, Canada
8Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
MD, MScMaxime Montembeault
1Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer’s Disease (StoP-AD), Montreal, Quebec, Canada
11Department of Psychiatry, McGill University, Montreal, Quebec, Canada
PhDPedro Rosa-Neto
8Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
10McGill Center for Research Studies in Aging, Montreal, Quebec, Canada
MDJean-Paul Soucy
8Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
MD, MScJohn C.S. Breitner
1Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer’s Disease (StoP-AD), Montreal, Quebec, Canada
11Department of Psychiatry, McGill University, Montreal, Quebec, Canada
MD, MPHHenrik Zetterberg
2Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
7Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
12Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
13UK Dementia Research Institute at UCL, London, UK
14Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China
15UW Department of Medicine, School of Medicine and Public Health, Madison, WI, USA
MD, PhDKaj Blennow
2Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
12Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
MD, PhDJudes Poirier
1Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer’s Disease (StoP-AD), Montreal, Quebec, Canada
11Department of Psychiatry, McGill University, Montreal, Quebec, Canada
PhDSylvia Villeneuve
1Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer’s Disease (StoP-AD), Montreal, Quebec, Canada
8Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
11Department of Psychiatry, McGill University, Montreal, Quebec, Canada
PhD
Posted May 09, 2024.
Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adults
Yara Yakoub, Fernando Gonzalez-Ortiz, Nicholas J. Ashton, Christine Déry, Cherie Strikwerda-Brown, Frédéric St-Onge, Valentin Ourry, Michael Schöll, Maiya R. Geddes, Simon Ducharme, Maxime Montembeault, Pedro Rosa-Neto, Jean-Paul Soucy, John C.S. Breitner, Henrik Zetterberg, Kaj Blennow, Judes Poirier, Sylvia Villeneuve, PREVENT-AD Research Group
medRxiv 2024.05.09.24307120; doi: https://doi.org/10.1101/2024.05.09.24307120
Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adults
Yara Yakoub, Fernando Gonzalez-Ortiz, Nicholas J. Ashton, Christine Déry, Cherie Strikwerda-Brown, Frédéric St-Onge, Valentin Ourry, Michael Schöll, Maiya R. Geddes, Simon Ducharme, Maxime Montembeault, Pedro Rosa-Neto, Jean-Paul Soucy, John C.S. Breitner, Henrik Zetterberg, Kaj Blennow, Judes Poirier, Sylvia Villeneuve, PREVENT-AD Research Group
medRxiv 2024.05.09.24307120; doi: https://doi.org/10.1101/2024.05.09.24307120
Subject Area
Subject Areas
- Addiction Medicine (375)
- Allergy and Immunology (690)
- Anesthesia (184)
- Cardiovascular Medicine (2763)
- Dermatology (236)
- Emergency Medicine (414)
- Epidemiology (12413)
- Forensic Medicine (10)
- Gastroenterology (784)
- Genetic and Genomic Medicine (4275)
- Geriatric Medicine (396)
- Health Economics (702)
- Health Informatics (2763)
- Health Policy (1023)
- Hematology (370)
- HIV/AIDS (880)
- Medical Education (404)
- Medical Ethics (112)
- Nephrology (455)
- Neurology (4058)
- Nursing (218)
- Nutrition (601)
- Oncology (2139)
- Ophthalmology (607)
- Orthopedics (251)
- Otolaryngology (313)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (479)
- Pediatrics (1150)
- Primary Care Research (471)
- Public and Global Health (6663)
- Radiology and Imaging (1455)
- Respiratory Medicine (886)
- Rheumatology (423)
- Sports Medicine (353)
- Surgery (466)
- Toxicology (57)
- Transplantation (193)
- Urology (171)